Phase 4Active, not recruitingINTERVENTIONAL
Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone
ClinicalTrials.gov · NCT04467983 · Registry updated: 2026-10-13
- Condition / research focus
- Osteoporosis, Postmenopausal
- Sponsor
- Hospital for Special Surgery, New York
- Countries with listed sites
- United States
- Registry dates and results
- Start: 2021-02-01. Completion: 2026-12-31 (may be estimated). No results posted in this registry response.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- Denosumab Injection (drug) — also listed as: Prolia
- Abaloparatide (drug) — also listed as: Tymlos
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
- Hospital for Special Surgery
New York, New York, United States
Site recruitment: Not reported